 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | ALETA-001 / Aleta Biotherap
Enrollment open, CAR T-Cell Therapy: A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies (clinicaltrials.gov) - Jan 4, 2024
P1/2, N=72, Recruiting, Sponsor: Cancer Research UK
Not yet recruiting --> Recruiting
- ALETA-001 / Aleta Biotherap
CAR T engagers encoding immune checkpoint inhibitors and immune-relevant cytokines stimulate CAR T cell activity against hematologic and solid tumors (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_698;
ALETA-001 is a biologic CTE that binds to CD20 and displays the CD19 extracellular domain (ECD)...Notably, all these functions are incorporated into the CTE, leaving CAR T engineering as separate tool. CTEs carrying multiple domains designed to simultaneously enhance functionality are being designed and evaluated and will be presented.
- | ALETA-001 / Aleta Biotherap
New P1/2 trial, CAR T-Cell Therapy: A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies (clinicaltrials.gov) - Sep 21, 2023
P1/2, N=72, Not yet recruiting, Sponsor: Cancer Research UK
- ||||| ALETA-001 / Aleta Biotherap
Review, CAR T-Cell Therapy: Cool @BioCentury wrote a nice #SITC22 review of synergy among therapeutic modalities, to better beat down cancers. Includes a profile of our lead program ALETA-001, heading into the clinic very soon. @BioAleta #celltherapy #TCE #carTcells (Twitter) - Nov 14, 2022
- ||||| ALETA-001 / Aleta Biotherap
CAR T-Cell Therapy: Aleta Biotherapeutics Receives Innovation Passport Designation for Biologic CAR T-Cell Therapy Engager ALETA-001 https://t.co/yM2bjDulU5 (Twitter) - Nov 7, 2022
- ALETA-001 / Aleta Biotherap
CAR-T engager proteins for the treatment of B cell cancers and acute myeloid leukemia (Section 30) - Mar 9, 2022 - Abstract #AACR2022AACR_4544;
ALETA-001 is a CAR-T Engager protein that contains the CD19 extracellular domain (ECD), an anti-CD20 VHH, and an anti-albumin VHH for half-life extension...Finally, CAR-T Engagers directed to AML antigens were able to bind each antigen individually, and mediated potent toxicity with the addition of CAR19 T cells.We conclude that the CAR-T Engager platform offers robust and modular anti-tumor functionality, featuring potent multi-antigen targeting for diverse indications. Finally, we can incorporate other useful immunomodulatory activities into Engager proteins.
- ALETA-001 / Aleta Biotherap
Characterization of Aleta-001, a CAR T Engager Designed to Optimize Responses and Prevent Relapses from CAR-19 Therapy (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_3296;
Patients who are enrolled will be dosed with the Aleta-001 Engager protein every two weeks. Aleta-001 has entered GMP production and IND enabling studies and will then enter Phase 1 dose escalation clinical studies in the UK.